Cited by 104Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

PICALM and Alzheimer’s Disease: An Update and Perspectives

Open access
Ando, Kunie, Nagaraj, Siranjeevi, Küçükali, Fahri, de Fisenne, Marie-Ange, Kosa, Andreea-Claudia, Doeraene, Emilie, Lopez Gutierrez, Lidia, Brion, Jean-Pierre +1 more·2022·Cells

Abstract

Genome-wide association studies (GWAS) have identified the PICALM (Phosphatidylinositol binding clathrin-assembly protein) gene as the most significant genetic susceptibility locus after APOE and BIN1. PICALM is a clathrin-adaptor protein that plays a critical role in clathrin-mediated endocytosis and autophagy. Since the effects of genetic variants of PICALM as AD-susceptibility loci have been confirmed by independent genetic studies in several distinct cohorts, there has been a number of in vitro and in vivo studies attempting to elucidate the underlying mechanism by which PICALM modulates AD risk. While differential modulation of APP processing and Aβ transcytosis by PICALM has been reported, significant effects of PICALM modulation of tau pathology progression have also been evidenced in Alzheimer’s disease models. In this review, we summarize the current knowledge about PICALM, its physiological functions, genetic variants, post-translational modifications and relevance to AD pathogenesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells11243994

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PICALM expression in patients with AD may also be influenced by cell type, MG state and disease stage.

    “Although our study indicates a reduced PICALM expression in LOAD-risk-allele iMGs, PICALM expression in patients with AD may also be influenced by cell type, MG state and disease stage31,56.”

    From PICALM Alzheimer’s risk allele causes aberrant lipid droplets in microglia (2025) · cites this paper as [31]

    Section 3.3.1 says PICALM expression is dysregulated during AD progression, while section 3.4 and Discussion section 4.1 describe differing expression across cell types in AD brains. Section 3.4 also reports microglial PICALM upregulation correlated with AD pathology, but the cited paper does not establish that microglial state itself influences PICALM expression. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • PICALM has a role in clathrin-mediated endocytosis in non-MG cells.

    “and the role of PICALM in clathrin-mediated endocytosis in non-MG cells31,32”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ando, K., Nagaraj, S., Küçükali, F., de Fisenne, M.-A., Kosa, A.-C., Doeraene, E., Lopez Gutierrez, L., Brion, J.-P., & Leroy, K.
Affiliations
  • Laboratory of Histology, Neuropathology and Neuroanatomy, Faculty of Medicine, Université Libre de Bruxelles, ULB Neuroscience Institute, 808 Route de Lennik, 1070 Brussels, Belgium
  • Université Libre de Bruxelles (BE)
  • University of Antwerp (BE)
Venue
Cells
Publisher
MDPI AG
Published
2022-12-10
Volume
11
Issue
24
Pages
3994
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4312125675
Cited by
104
References
165
Citations by year
2026: 32 · 2025: 34 · 2024: 25 · 2023: 13
FWCI
2.48
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Belgian Fonds de la Recherche Scientifique Médicale (2019/0027, 14001, 2021/0028)
  • Fund Aline (King Baudouin Foundation) (2019/0027, 14001, 2021/0028)
  • Foundation for Alzheimer Research (FRA/SAO) (2019/0027, 14001, 2021/0028)
  • Génicot Fund of ULB (2019/0027, 14001, 2021/0028)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
PICALM, Alzheimer's disease, genetic susceptibility, clathrin-mediated endocytosis, autophagy, clathrin adaptor proteins, APP processing, tau pathology, post-translational modification, genetic variants
MeSH terms
Alzheimer Disease, Clathrin, Humans, Genetic Predisposition to Disease, Monomeric Clathrin Assembly Proteins, Genome-Wide Association Study, Genetic Loci

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review